Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OGEN
stocks logo

OGEN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q4
--
--
-90.009
+455.56%
Estimates Revision
Stock Price
Go Down
down Image
-21.15%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Oragenics Inc (OGEN.A) is -1.14, compared to its 5-year average forward P/E of -1.39. For a more detailed relative valuation and DCF analysis to assess Oragenics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.39
Current PE
-1.14
Overvalued PE
0.31
Undervalued PE
-3.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.10
Undervalued EV/EBITDA
-0.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
23.90
Current PS
0.00
Overvalued PS
128.94
Undervalued PS
-81.14
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 5510.84% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 5510.84% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

OGEN News & Events

Events Timeline

(ET)
2025-10-21
08:14:41
Oragenics Meets NYSE Compliance Requirements Again
select
2025-10-07 (ET)
2025-10-07
09:17:53
Oragenics and Receptor.AI Collaborate to Speed Up Pipeline Development
select
2025-08-11 (ET)
2025-08-11
08:48:57
Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-12Newsfilter
Oragenics Q3 2025 Update for Shareholders

  • Operational Achievements: Oragenics regained compliance with NYSE American listing standards and established the necessary infrastructure for its Phase IIa clinical trial of ONP-002 in Australia, marking a significant step towards its first drug entering clinical trials.

  • Strategic Partnerships: The company formed a collaboration with Receptor.AI to enhance its drug development pipeline, aiming to leverage AI for identifying promising therapeutic candidates beyond its lead drug, ONP-002.

  • Financial Discipline: Oragenics strengthened its balance sheet through a $16.5 million capital raise, eliminating debt and restoring stockholder equity, while also demonstrating operational efficiency with reduced R&D and operating expenses.

  • Future Milestones: Upcoming catalysts include finalizing HREC amendments for clinical site onboarding, initiating the Phase IIa trial, and preparing for U.S. Phase IIb trials, alongside continued research for expanding its therapeutic portfolio.

[object Object]
Preview
7.5
10-08Yahoo Finance
Oragenics Collaborates with Receptor.AI on Brain Health Product Line

  • Strategic Collaboration: Oragenics has partnered with Receptor.AI to accelerate the development of new pharmaceutical candidates for brain health, utilizing AI modeling to optimize receptor binding profiles for compounds added to its portfolio in 2023.

  • Clinical Trials and Broader Scope: The company is advancing its clinical studies for ONP-002, currently in Phase IIa trials in Australia, with plans for Phase IIb trials in the US, while aiming to discover treatments for various neurological and psychiatric disorders through AI-guided laboratory testing.

[object Object]
Preview
9.0
08-11Newsfilter
Oragenics Q2 2025 Shareholder Update

  • Advancements in Neurotrauma Treatment: Oragenics, Inc. is progressing towards becoming the first company to receive FDA approval for a pharmacological treatment for concussion with its lead candidate ONP-002, utilizing proprietary intranasal delivery technology aimed at transforming neurotrauma care.

  • Strategic Growth and Market Potential: The company has secured key partnerships and funding to support clinical trials and manufacturing capabilities, positioning itself within a rapidly growing nasal drug delivery market projected to exceed $40 billion by 2030, while addressing the significant unmet medical need for effective concussion therapies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Oragenics Inc (OGEN) stock price today?

The current price of OGEN is 0.8516 USD — it has decreased -1.5 % in the last trading day.

arrow icon

What is Oragenics Inc (OGEN)'s business?

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.

arrow icon

What is the price predicton of OGEN Stock?

Wall Street analysts forecast OGEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGEN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Oragenics Inc (OGEN)'s revenue for the last quarter?

Oragenics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Oragenics Inc (OGEN)'s earnings per share (EPS) for the last quarter?

Oragenics Inc. EPS for the last quarter amounts to -1.96 USD, decreased -82.69 % YoY.

arrow icon

What changes have occurred in the market's expectations for Oragenics Inc (OGEN)'s fundamentals?

The market is revising No Change the revenue expectations for OGEN for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -21.15%.
arrow icon

How many employees does Oragenics Inc (OGEN). have?

Oragenics Inc (OGEN) has 3 emplpoyees as of December 05 2025.

arrow icon

What is Oragenics Inc (OGEN) market cap?

Today OGEN has the market capitalization of 3.55M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free